Heron Therapeutics (HRTX) Research & Development (2010 - 2026)

Heron Therapeutics (HRTX) has reported Research & Development for 17 consecutive years, with $14.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 22.33% year-over-year to $14.2 million; the trailing twelve-month figure through Jun 2026 stood at $53.6 million (up 16.83% YoY), and the FY2025 full-year result was $49.1 million, up 4.2% from the prior year.
• Research & Development fell to $14.2 million in Q2 2026 per HRTX's latest filing, from $14.3 million in the prior quarter.
• Across five years, Research & Development topped out at $42.1 million in Q1 2022 and bottomed at -$13.7 million in Q4 2022.
• Historically, Research & Development has averaged $15.3 million across 5 years, with a median of $12.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development plunged 147.6% in 2022, then soared 189.69% in 2023.
• Over 5 years, Research & Development stood at -$13.7 million in 2022, then jumped by 189.69% to $12.3 million in 2023, then slipped by 10.31% to $11.1 million in 2024, then climbed by 10.64% to $12.2 million in 2025, then rose by 15.75% to $14.2 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $14.2 million, $14.3 million, and $12.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.